nox 2

NOX2-IN-2 diTFA (compound 33) is an effective inhibitor of NOX2, targeting the p47phox-p22phox protein-protein interaction with a Ki of 0.24 μM. This compound effectively suppresses the production of ROS generated by NOX2 in cells.

NOX2-IN-2 (compound 33) is a potent inhibitor of NOX2, disrupting the p47phox-p22phox protein-protein interaction with a dissociation constant (Ki) of 0.24 μM, and effectively suppressing reactive oxygen species (ROS) production from NOX2 in cellular contexts [1].

NOX2-IN-1 (compound 10) is an inhibitor of nicotinamide adenine dinucleotide phosphate oxidase isoform 2 (NOX2), disrupting the p47phox-p22phox protein-protein interaction with high binding affinities and potent activity in cellular assays [1].

APX-115 (Ewha-18278) (Ewha-18278) is a potent, orally active pan NADPH oxidase (Nox) inhibitor (Kis: 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2, and Nox4). APX-115 effectively prevents kidney injury.

ML-090 is NOX1-specific inhibitor(IC50 = 90 nM) which is >100 selectivity for NOX1 over NOX2, NOX3, NOX4 (all IC50s >10 μM).

4',6,7-Trimethoxyisoflavone promotes wound healing through NOX2 induction, which leads to collective migration and MMP activation.

APX-115 free base (Ewha-18278 free base) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with inhibition constants (Kis) of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2, and Nox4, respectively, and it effectively prevents kidney injury.

Phox-I2 is an NOX2-specific inhibitor. Phox-I2 reverts ROS-accumulation and leads to refusion of mitochondrial networks.

gp91 ds-tat is a NADPH oxidase (NOX2) inhibitor that reduces NOX2 expression.

NOX2-IN-3 (compound 3), functioning as an inhibitor of NOX2 (NADPH Oxidase 2), enhances the sensitivity of tumor cells to MRTX1133 [1].

NOX5-IN-2 (Compound 17) is a selective inhibitor of NADPH oxidase 5 (NOX5) with an IC50 value of 0.70 μM. It effectively suppresses NOX5-dependent ROS production in freestyle293 cells, exhibiting an EC50 of 1.8 μM. NOX5-IN-2 is useful for researching NOX-related diseases, such as cardiovascular disorders, cancer, and neuroinflammation.

Seltorexant hydrochloride is a selective, orally active and high-affinity antagonist of OX2R with pKi values of 8.0 and 8.1 for human and rat OX2R.

Seltorexant (JNJ-42847922) crosses the blood-brain barrier and quickly occupies OX2R binding sites in the rat brain. Seltorexant is a high-affinity and selective orexin-2 receptor antagonist (pKi: 8.0 and 8.1 for human and rat OX2R).

GLX351322 is NADPH Oxidase 4 Inhibitor with IC50 of 5 μM.

1. Decursin (Decursinol angelate) is able to attenuate kainic acid-induced seizures and could have potential as an antiepileptic drug. 2. Decursin exhibits hepatoprotective effects , potentially by inhibiting the TGF-β1 induced NOX activation and Smad signaling. 3. Decursin has anti-cancer activity , mediated suppression of the PKCα, MAPK and NF-κB pathways in MCF-7 cells. 4. Decursin exhibits cytotoxicity against various human cancer cells and to possess anti-amnesic activity in vivo through the inhibition of AChE activity.

GLX481304 is a selective Nox-2 and Nox-4 inhibitor, exhibiting IC50 values of 1.25 μM. It inhibits ROS production in isolated mouse cardiomyocytes and enhances their contractility. This compound is useful in research focused on ischemic cardiac injury [1].